Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Neuropeptide receptors like those for Vasoactive Intestinal Peptide (VIP), Bombesin, Substance P, and Somatostatin are often overexpressed in various cancers.
• Primary human colon adenocarcinoma cells synthesize and secrete these native neuropeptides and express high-affinity receptors on their surface.

Purpose of the Study:

• To design and synthesize novel peptide analogs targeting overexpressed neuropeptide receptors.
• To evaluate the anticancer activity and safety of a novel peptide combination (DRF7295) derived from these analogs.

Main Methods:

• Screening of peptide hormone analogs for cytotoxic activity against tumor cell proliferation.
• In vitro assessment of DRF7295 activity across a broad panel of human tumor cell lines.
• In vivo efficacy studies using xenograft models of gastrointestinal cancers (colon, duodenum).
• Comprehensive safety evaluation, including acute and long-term toxicity and safety pharmacology studies.

Main Results:

• DRF7295 exhibited potent in vitro anticancer activity, particularly against gastrointestinal tumor cells (colon, pancreas, duodenum).
• Moderate activity was observed in glioblastoma, prostate, leukemia, and oral cancer cell lines.
• In vivo studies in colon and duodenum xenografts showed significant tumor regression (T/C% < 40%).
• Safety studies indicated DRF7295 is safe upon systemic administration with no significant adverse pharmacological effects.

Conclusions:

• DRF7295, a novel combination of four synthetic neuropeptide analogs, demonstrates significant anticancer potential, especially in gastrointestinal malignancies.
• The drug's mechanism likely involves targeting overexpressed neuropeptide receptors on tumor cells.
• DRF7295 presents a promising therapeutic candidate with a favorable safety profile for systemic cancer treatment.